Online inquiry

IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ479MR)

This product GTTS-WQ479MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ479MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2669MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ8556MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ14974MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ3764MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ12753MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ3570MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ3589MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ896MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW